公司资料
AEON Biopharma 股价、新闻与催化剂
- 股票代码:
- AEON
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
0.26 USD (-7.12%)
收盘价
最后更新: 2026年8月17日
19.7M USD
市值
股价为何变动
As of Aug 17, 2026, AEON closed down 7.12% at $0.2555. No new same-company headline was identified in the current news window.
公司概览
业务概览
AEON Biopharma is a clinical-stage neurotoxin company focused on botulinum toxin-based therapies and the potential to build a differentiated commercial asset in aesthetics and neurology. The investment case centers on whether the company can turn a highly specialized product profile into a durable franchise.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, AEON sits in the specialty therapeutics segment. Its profile is shaped more by product execution and regulatory positioning than by broad pipeline breadth.
商业模式特征
AEON depends on clinical progress, commercialization strategy, and the ability to convert a focused asset base into repeatable revenue. Investors typically watch launch timing, commercial access, and strategic financing decisions.
生物医药行业定位
AEON sits in a narrow but catalyst-sensitive corner of biotech where a single program can drive most of the valuation. Compared with larger peers, the stock is more exposed to execution risk and inflection-point revaluation.
未来催化剂
- The next three months should center on ABP-450 biosimilar development, especially follow-up with the FDA on the analytical package and the next BPD meeting steps that determine whether the program can stay on a clean regulatory path. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the next regulatory or label step instead of just the current filing.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。